Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis

BACKGROUND & AIMS: The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evaluated in a phase II, double-blind, placebo-controlled study as potential second-line therapy for patients with primary biliary cholangitis (PBC) with an inadequate urso...

Descripción completa

Detalles Bibliográficos
Autores principales: Schramm, Christoph, Wedemeyer, Heiner, Mason, Andrew, Hirschfield, Gideon M., Levy, Cynthia, Kowdley, Kris V., Milkiewicz, Piotr, Janczewska, Ewa, Malova, Elena Sergeevna, Sanni, Johanne, Koo, Phillip, Chen, Jin, Choudhury, Subhajit, Klickstein, Lloyd B., Badman, Michael K., Jones, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576902/
https://www.ncbi.nlm.nih.gov/pubmed/36267872
http://dx.doi.org/10.1016/j.jhepr.2022.100544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576902/
https://www.ncbi.nlm.nih.gov/pubmed/36267872
http://dx.doi.org/10.1016/j.jhepr.2022.100544

Ejemplares similares